Patents by Inventor Jeff A. Zablocki

Jeff A. Zablocki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of hepatitis C virus
    Patent number: 10335409
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: July 2, 2019
    Assignee: Gilead Pharmasset LLC
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • Toll like receptor modulator compounds
    Patent number: 10285990
    Abstract: The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: May 14, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Richard L. Mackman, Samuel E. Metobo, Michael R. Mish, Hyung-Jung Pyun, Jeff Zablocki
  • Tank-binding kinase inhibitor compounds
    Patent number: 10259811
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Juan Arnaldo Guerrero, Joshua Aaron Kaplan, John Edward Knox, Jr., Devan Naduthambi, Barton W. Phillips, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jeff Zablocki
  • TANK-BINDING KINASE INHIBITOR COMPOUNDS
    Publication number: 20190016717
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Application
    Filed: July 24, 2018
    Publication date: January 17, 2019
    Inventors: Zhimin DU, Juan Arnaldo GUERRERO, Joshua Aaron KAPLAN, John Edward KNOX, JR., Devan NADUTHAMBI, Barton W. PHILLIPS, Chandrasekar VENKATARAMANI, Peiyuan WANG, William J. WATKINS, Jeff ZABLOCKI
  • INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20190008858
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: June 11, 2018
    Publication date: January 10, 2019
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa A. Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila Zipfel
  • COMPOUNDS FOR THE TREATMENT OF ADDICTION
    Publication number: 20180338989
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 29, 2018
    Applicant: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
  • Fused heterocyclic compounds as CaM kinase inhibitors
    Patent number: 10100058
    Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 16, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
  • BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS
    Publication number: 20180282316
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna M. Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Andrew Lee, Ruben Martinez, Samuel E. Metobo, Michael R. Mish, Manuel Munoz, Sophia L. Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Tank-binding kinase inhibitor compounds
    Patent number: 10072001
    Abstract: Compounds having the following formula (I) and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: September 11, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Juan Arnaldo Guerrero, Joshua Aaron Kaplan, John Edward Knox, Jr., Devan Naduthambi, Barton W. Phillips, Chandrasekar Venkataramani, Peiyuan Wang, William J. Watkins, Jeff Zablocki
  • Benzimidazole derivatives as bromodomain inhibitors
    Patent number: 10017501
    Abstract: This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, and R5 are described herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: July 10, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Gregory Chin, Britton Kenneth Corkey, Jinfa Du, Kristyna Elbel, Robert H. Jiang, Tetsuya Kobayashi, Rick Lee, Ruben Martinez, Samuel E. Metobo, Michael Mish, Manuel Munoz, Sophie Shevick, David Sperandio, Hai Yang, Jeff Zablocki
  • Syk inhibitors
    Patent number: 10005774
    Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein X1, X2, X3, R2, R3, R4, R5, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 26, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Jayaraman Chandrasekhar, Kevin S. Currie, Zhimin Du, Julie Farand, Juan A. Guerrero, Ashley A. Katana, Darryl Kato, Jeffrey E. Kropf, Scott E. Lazerwith, Seung H. Lee, Jiayao Li, John O. Link, Jennifer R. Lo, Nicholas Mai, Scott A. Mitchell, Gregory Notte, Hyung-jung Pyun, Michael Sangi, Aaron C. Schmitt, Adam J. Schrier, Kirk L. Stevens, Chandrasekar Venkataramani, William J. Watkins, Jin-Ming Xiong, Jianjun Xu, Zheng-Yu Yang, Jeff Zablocki, Zhongdong Zhao, Sheila Zipfel
  • Compounds for the treatment of addiction
    Patent number: 9987295
    Abstract: Disclosed are novel compounds having the structure of Formula (I): which are useful for treating mammals for dependence upon substances of addiction, for example addiction to a dopamine-producing agent such as cocaine, morphine, amphetamines, nicotine, and/or alcohol. Also disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula (I) and methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 5, 2018
    Assignee: Amygdala Neurosciences, Inc.
    Inventors: Carina E. Cannizzaro, Michael Graupe, Juan A. Guerrero, Yafan Lu, Robert G Strickley, Chandrasekar Venkataramani, Jeff Zablocki
  • FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
    Publication number: 20180148457
    Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 31, 2018
    Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
  • TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
    Publication number: 20180086755
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 29, 2018
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 9920018
    Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R2, R3, R4, p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: March 20, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Yafan Lu, Jeff Zablocki
  • TOLL LIKE RECEPTOR MODULATOR COMPOUNDS
    Publication number: 20180065938
    Abstract: This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.
    Type: Application
    Filed: August 31, 2017
    Publication date: March 8, 2018
    Inventors: Gregory Chin, Richard L. Mackman, Michael R. Mish, Jeff Zablocki
  • INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20170313745
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein the various substituents are defined herein, methods of using said compounds, and pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: March 10, 2017
    Publication date: November 2, 2017
    Inventors: Kyla L. Bjornson, Kapil K. Karki, John O. Link, Hyung-jung Pyun, Adam J. Schrier, Kirk L. Stevens, James G. Taylor, Randall W. Vivian, Jeff Zablocki, Sheila M. Zipfel
  • INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20170290827
    Abstract: Compounds of Formula I are disclosed As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.
    Type: Application
    Filed: April 14, 2017
    Publication date: October 12, 2017
    Inventors: Kyla Bjornson, Eda Canales, Jeromy J. Cottell, Kapil K. Karki, Ashley A. Katana, Darryl Kato, Tetsuya Kobayashi, John O. Link, Ruben Martinez, Barton W. Phillips, Hyung-Jung Pyun, Michael Sangi, Adam J. Schrier, Dustin Siegel, James G. Taylor, Chinh V. Tran, Teresa Alejandra Trejo Martin, Randall W. Vivian, Zheng-Yu Yang, Jeff Zablocki, Sheila M. Zipfel
  • Process for preparing an A2A-adenosine receptor agonist and its polymorphs
    Patent number: RE47301
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 19, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Robert Seemayer, Travis Lemons
  • 2-(N-pyrazolo)adenosines with application as adenosine Areceptor agonists
    Patent number: RE47351
    Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli